RubinowDRRoy-ByrneP. Premenstrual syndromes: Overview from a methodologic perspective. Am J Psychiatry1984; 141: 163–72.
2.
MassilHYO'BrienPM. Approach to management of premenstrual syndrome. Clin Obstet Gynecol1987; 30: 443–52.
3.
DubovskySLFranksRD. Intercellular calcium ions in affective disorder: A review and a hypothesis. Biol Psychiatry1983; 18: 781–97.
4.
KeyesWR. General evaluation of premenstrual symptoms. Clin Obstet Gynecol1987; 30: 396–415.
5.
Deleon-JonesFASteinbergJDekirmejianHGarverD. MHPG excretion during the menstrual cycle of women. Common Psychopharmacol1978; 2: 267–74.
6.
PriceWAGianniniAJ. The use of clonidine in the premenstrual tension syndrome. J Clin Pharmacol1984; 24: 463–5.
7.
MattssonBSchoultzB. A comparison between lithium, placebo and a diuretic in premenstrual tension. Acta Psychiatr Scand1974; 255: 75–83.
8.
MagosA. Advances in the treatment of the premenstrual syndrome. Br J Obstet Gynaecol1990; 97: 7–10.
9.
SmithSRinehartJSRuddockVESchiffI. Treatment of premenstrual syndrome with alprazolam: Results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol1987; 70: 37–42.
10.
GoldsteinJA. Calcium channel blockers in the treatment of panic disorder (letter). J Clin Psychiatry1985; 46: 546.
11.
PriceWAGianniniAJ. Verapamil in the treatment of premenstrual syndrome: Case report. J Clin Psychiatry1986; 47: 213–4.
12.
OverallJE. Brief psychiatric rating scale. In: Staff of research and education association. Handbook of psychiatric rating scales. New York: Research and Education Association, 1981: 65–73.
13.
DeickenRF. Verapamil treatment of premenstrual syndrome. Biol Psychiatry1988; 24: 689–92.
14.
SteinerMHaskettRFCarrolBJ. Premenstrual tension syndrome: The development of research diagnositic criteria and new rating scales. Acta Psychiatr Scand1980; 62: 177–90.
15.
RobertHJ. Perspective on vitamin E as therapy. JAMA1981; 246: 129–31.
16.
BarkerBMBenderBA. Vitamins in medicine. 4th ed.London: W. Heinemann Medical Books, 1980: 147–66.
17.
OgunmekanAOHwangPA. A randomized, double-blind study, placebo-controlled, clinical trial of D-alpha-tocopherol acetate (vitamin E), as add-on therapy, for epilepsy in children. Epilepsia1989; 30: 84–9.
18.
JerrettSAJeffersonDMengelCE. Seizures, H2O2 formation and lipid peroxides in brain during exposure to oxygen under high pressure. Aerospace Med1973; 44: 40–4.
19.
SoderfeldtBBennowGKalimoHOlssonYSiesjoBK. Influence of systemic factors on experimental epileptic brain injury: Structural changes accompanying bicuculline induced seizures in rats following manipulations of tissue oxygenation or alpha-tocopherol levels. Acta Neuropathol1983; 60: 80–91.
20.
WillmoreLJTriggsWJGrayJD. The role of iron-induced hippocampal peroxidation in acute epileptogenesis. Brain Res1986; 382: 442–6.
21.
OgunmekanAO. Relationship between age and vitamin E level in epileptic children and normal children. Am J Clin Nutr1979; 32: 2269–71.
22.
OgunmekanAO. Plasma vitamin E levels in normal children and in epileptic children with and without anticonvulsant drug therapy. Trop Geog Med1985; 37: 175–7.
23.
HigashiATamariHIkedaT. Serum vitamin E concentrations in patients with severe multiple handicaps treated with anticonvulsants. Pediatr Pharmacol1980; 1: 129–34.
24.
KovalenkoVMKovalenkoVSProninaI. Alpha-tocopherol in the complex treatment of several forms of epilepsy. Zh Nevropatol Psikhiatr1984; 6: 892–7.
25.
Physicians' desk reference. 44th ed.Oradell, NJ: Medical Economics, 1990: 2242.
26.
StacklWHasunRMarbergerM. Intracavemous injection of prostaglandin E1 in impotent men. J Urol1988; 140: 66–8.
27.
LueTFTanaghoEA. Physiology of erection and pharmacological management of impotence. J Urol1987; 137: 829–36.
28.
HedlundHAnderssonK. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol1985; 134: 1245–50.
SchramekPWaldhauserM. Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction. Br J Clin Pharmacol1989; 28: 567–71.
31.
HwangTIYangCRWangSJ. Impotence evaluated by the use of prostaglandin E1. J Urol1989; 141: 1357–9.
32.
IshiiNWatanabeHIrisawaC. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol1989; 141: 323–5.
33.
SchramekPDorningerRWaldhauserMKonecryPPorpaczyP. Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Br J Urol1990; 65: 68–71.
34.
WaldhauserMSchramekP. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol1988; 140: 525–7.
35.
SzaszMDStevensonRWLeeLSandersHD. Induction of penile erection by intracavemosal injection: A double-blind comparison of phenoxybenzamine versus papaverine-phentolamine versus saline. Arch Sex Behav1987; 16: 371–8.
36.
SarosdyMFHudnallCHEricksonDRHardinTCNovickiDE. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence. J Urol1989; 141: 551–3.
37.
ReissH. Use of prostaglandin E1 for papaverine-failed erections. Urology1989; 33: 15–6.
38.
LeeLMStevensonRWSzaszG. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: A double-blind comparison. J Urol1989; 141: 549–50.
39.
BenardFLueTF. Self-administration in the pharmacological treatment of impotence. Drugs1990; 39: 394–8.
40.
SeidmonEJSamahaAM. The pH analysis of papaverine-phentolamine and prostaglandin E1 for pharmacological erection. J Urol1989; 141: 1458–9.
41.
SidiAAReddyPKChenKK. Patient acceptance of and satisfaction with vasoactive intracavemosal pharmacotherapy for impotence. J Urol1988; 140: 293–4.
42.
SidiAACameronJSDuffyLMLangePH. Intracavemous drug-induced erections in the management of male erectile dysfunction: Experience with 100 patients. J Urol1986; 135: 704–6.
43.
KraneRJGoldsteinEDe TejadaSqenz I. Medical progress: Impotence. N Engl J Med1989; 321: 1648–57.
44.
BrindleyGS. Cavemosal alpha-blockage: A new technique for investigating and treating erectile impotence. Br J Psychiatry1983; 143: 332–7.